Retrospective observation of subacute thyroiditis before and during the COVID-19 vaccination campaign in a single secondary endocrine centre in the Savona district, Liguria, Italy.

IF 1.8 Q3 ENDOCRINOLOGY & METABOLISM Thyroid Research Pub Date : 2022-11-02 DOI:10.1186/s13044-022-00139-z
Massimo Giusti, Marilena Sidoti
{"title":"Retrospective observation of subacute thyroiditis before and during the COVID-19 vaccination campaign in a single secondary endocrine centre in the Savona district, Liguria, Italy.","authors":"Massimo Giusti,&nbsp;Marilena Sidoti","doi":"10.1186/s13044-022-00139-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clinicians should be aware that subacute thyroiditis (SAT) might be an under-reported adverse effect of COVID-19 vaccines.</p><p><strong>Aim: </strong>In records from endocrinological examinations, we reviewed the incidence of diagnoses of SAT from 2000 to 2020 and during the 2021 COVID-19 vaccination campaign.</p><p><strong>Methods: </strong>Review of electronic records from June to December in each year from 2000 to 2021.</p><p><strong>Results: </strong>From 2000 to 2020, 51 patients in our centre had SAT (0.6%). From June to December 2021, 7 females were diagnosed with SAT after vaccination. The percentage of SAT in 2021 medical files was 1.5%. SAT diagnoses significantly (P = 0.03) increased in 2021 in comparison with the 2000-2020 period. The median age of SAT patients in 2021 (51 years; IQR 35-66 years) was higher than in the 2000-2020 period (45 years, IQR 38-52 years; P = 0.05).</p><p><strong>Conclusion: </strong>To date, few cases of SAT after COVID-19 vaccinations have been described in the literature, with sub-clinical, normal or increased thyroid function during 1-3-month follow-up. Our findings indicate that SAT after COVID-19 vaccination occurs more frequently than in other virus-related cases and at a greater age. Our observation of a local increase in SAT during the 2021 COVID-19 vaccination campaign indicates that physicians should be aware of this infrequent side effect, which must be considered and monitored after COVID-19 vaccination.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":" ","pages":"21"},"PeriodicalIF":1.8000,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628123/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13044-022-00139-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clinicians should be aware that subacute thyroiditis (SAT) might be an under-reported adverse effect of COVID-19 vaccines.

Aim: In records from endocrinological examinations, we reviewed the incidence of diagnoses of SAT from 2000 to 2020 and during the 2021 COVID-19 vaccination campaign.

Methods: Review of electronic records from June to December in each year from 2000 to 2021.

Results: From 2000 to 2020, 51 patients in our centre had SAT (0.6%). From June to December 2021, 7 females were diagnosed with SAT after vaccination. The percentage of SAT in 2021 medical files was 1.5%. SAT diagnoses significantly (P = 0.03) increased in 2021 in comparison with the 2000-2020 period. The median age of SAT patients in 2021 (51 years; IQR 35-66 years) was higher than in the 2000-2020 period (45 years, IQR 38-52 years; P = 0.05).

Conclusion: To date, few cases of SAT after COVID-19 vaccinations have been described in the literature, with sub-clinical, normal or increased thyroid function during 1-3-month follow-up. Our findings indicate that SAT after COVID-19 vaccination occurs more frequently than in other virus-related cases and at a greater age. Our observation of a local increase in SAT during the 2021 COVID-19 vaccination campaign indicates that physicians should be aware of this infrequent side effect, which must be considered and monitored after COVID-19 vaccination.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
意大利利古里亚萨沃纳区单一二级内分泌中心COVID-19疫苗接种运动前和期间亚急性甲状腺炎的回顾性观察
背景:临床医生应该意识到亚急性甲状腺炎(SAT)可能是COVID-19疫苗的一种未被报道的不良反应。目的:在内分泌检查记录中,我们回顾了2000年至2020年和2021年COVID-19疫苗接种运动期间SAT诊断的发生率。方法:对2000年至2021年每年6月至12月的电子病历进行复核。结果:从2000年到2020年,我们中心有51例患者患有SAT(0.6%)。2021年6月至12月,7名女性在接种疫苗后被诊断为SAT。2021年医疗档案中SAT的比例为1.5%。与2000-2020年相比,2021年的SAT诊断显著增加(P = 0.03)。2021年SAT患者的中位年龄(51岁;IQR 35 ~ 66年)高于2000 ~ 2020年(45年,IQR 38 ~ 52年);p = 0.05)。结论:迄今为止,文献中很少有COVID-19疫苗接种后出现SAT的病例,随访1-3个月甲状腺功能亚临床、正常或增加。我们的研究结果表明,与其他病毒相关病例相比,COVID-19疫苗接种后发生SAT的频率更高,年龄也更大。我们观察到2021年COVID-19疫苗接种运动期间局部SAT增加,这表明医生应该意识到这种罕见的副作用,在COVID-19疫苗接种后必须考虑和监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thyroid Research
Thyroid Research Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
3.10
自引率
4.50%
发文量
21
审稿时长
8 weeks
期刊最新文献
Identification of recurrent pathogenic SERPINA7 mutation causing coexistence of TBG-CD and hypothyroidism in Indian pedigrees: in Silico structural analysis of mutant TBG and literature reappraisal. Assessing the clinical diagnostic utility of multiplex ddPCR assays in thyroid nodules. Evaluation and projection of the global burden of thyroid cancer from 1990 to 2035: an analysis based on the Global Burden of Disease Study. Iodide for the management of Graves' disease in pregnancy. Association of hippocampus, entorhinal cortex, and amygdala with thyroid function: a bilateral volumetric analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1